Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

According to the American college of rheumatology, more than 790,000 knee replacements are performed annually in the U.S. and ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

TNX-102 SL, a sublingual cyclobenzaprine HCl formulation, is safe and effective for treating fibromyalgia symptoms, according to study results presented at the American College of Rheumatology (ACR) ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...